Elanco Animal Health Inc at TD Cowen Healthcare Conference Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Steve Scala - TD Cowen - Analyst : Right. Maybe, we can drill into 2025, in particular. What scenarios would lead to results that would be at the high end of the guidance range? And what might lead to, maybe, at the lower end?

Question: Steve Scala - TD Cowen - Analyst : You spoke a bit about the cadence of innovation sales in '25. But, as we look a little bit beyond that, is it upward and to the right? How should we expect the innovation sales to progress, say, over the next 18, 24 months?

Question: Steve Scala - TD Cowen - Analyst : By the way, if there's any questions in the room, please just raise your hand and we'll get your questions addressed. And, one more, relative to the complexion of growth and that is the 2% price growth that we saw. Is that the new normal for the intermediate to longer term? Or is that a less sustainable dynamic? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 03, 2025 / 8:10PM, ELAN.N - Elanco Animal Health Inc at TD Cowen Healthcare Conference

Question: Steve Scala - TD Cowen - Analyst : And, specifically, what are the factors that are capping that?

Question: Steve Scala - TD Cowen - Analyst : With that, I'll turn it over to my colleague Chris.

Question: Steve Scala - TD Cowen - Analyst : Questions from the audience? Okay. We are out of time. So thank you so much for making the journey to be with us. And we look forward to watching Elanco, over the next 10 years.